Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -63.59% is in line with its 4-year average of -66.52%, around the middle of its 4-year range (-183.14%–11.37%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.46% above its 12-month average of -64.53%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -63.59%.
RETURN ON EQUITY (ROE)
-63.59%
RETURN ON EQUITY (ROE) AVG TTM
-64.53%
RETURN ON EQUITY (ROE) AVG 3Y
-64.55%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.46%
CURRENT VS 3Y AVG
+1.48%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.17%
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
-66.60%
vs the sector median at left
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.09B
Return on Equity (ROE)
-63.59%
TTM Avg
-64.53%
3Y Avg
-64.55%
5Y Avg
N/A
Market Cap
$3.15B
Return on Equity (ROE)
12.93%
TTM Avg
-48.70%
3Y Avg
-135.42%
5Y Avg
-110.19%
Market Cap
$3.16B
Return on Equity (ROE)
-61.24%
TTM Avg
-42.47%
3Y Avg
-32.58%
5Y Avg
-25.72%
Market Cap
$3.25B
Return on Equity (ROE)
-11.83%
TTM Avg
-25.64%
3Y Avg
-7.84%
5Y Avg
-12.83%
Market Cap
$2.88B
Return on Equity (ROE)
-73.97%
TTM Avg
-48.15%
3Y Avg
-105.34%
5Y Avg
-79.84%
Market Cap
$2.87B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$2.87B
Return on Equity (ROE)
2.04%
TTM Avg
-6.01%
3Y Avg
-7.18%
5Y Avg
-5.00%
Market Cap
$3.44B
Return on Equity (ROE)
29.12%
TTM Avg
31.38%
3Y Avg
-1.34%
5Y Avg
-13.55%
Market Cap
$2.69B
Return on Equity (ROE)
95.64%
TTM Avg
115.72%
3Y Avg
76.74%
5Y Avg
3213.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.09B | -63.59% | -64.53% | -64.55% | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 12.93% | -48.70% | -135.42% | -110.19% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -61.24% | -42.47% | -32.58% | -25.72% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | -11.83% | -25.64% | -7.84% | -12.83% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -73.97% | -48.15% | -105.34% | -79.84% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 29.28% | 27.86% | 4.54% | -12.45% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 2.04% | -6.01% | -7.18% | -5.00% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 29.12% | 31.38% | -1.34% | -13.55% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 95.64% | 115.72% | 76.74% | 3213.80% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -56.91% | -24.13% | -9.83% | -11.19% |
ROE
-63.6%
ROA
-57.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -63.59% |
| 2026-03-31 | -54.95% |
| 2025-12-31 | -47.41% |
| 2025-09-30 | -44.96% |
| 2025-06-30 | -111.75% |
| 2025-03-31 | -108.66% |
| 2024-12-31 | -183.14% |
| 2024-09-30 | -132.24% |
| 2024-06-30 | -63.48% |
| 2024-03-31 | -21.91% |
| 2023-12-31 | 11.37% |
| 2023-09-30 | 0.44% |
| 2023-06-30 | -18.85% |
| 2023-03-31 | -42.24% |
| 2022-12-31 | -58.24% |
| 2022-09-30 | -127.76% |
| 2022-06-30 | -79.57% |
| 2022-03-31 | -50.32% |
